ImmunoCellular Therapeutics Probability of Future Pink Sheet Price Finishing Over 0.52
ImmunoCellular Therapeutics' future price is the expected price of ImmunoCellular Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of ImmunoCellular Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Please specify ImmunoCellular Therapeutics' target price for which you would like ImmunoCellular Therapeutics odds to be computed.
ImmunoCellular |
ImmunoCellular Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ImmunoCellular Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ImmunoCellular Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ImmunoCellular Therapeutics is not yet fully synchronised with the market data | |
| ImmunoCellular Therapeutics has some characteristics of a very speculative penny stock | |
| ImmunoCellular Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.15 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ImmunoCellular Therapeutics currently holds about 933.15 K in cash with (2.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 95.0% of the company shares are held by company insiders |
ImmunoCellular Therapeutics Technical Analysis
ImmunoCellular Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. ImmunoCellular Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of ImmunoCellular Therapeutics. In general, you should focus on analyzing ImmunoCellular Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
ImmunoCellular Therapeutics Predictive Forecast Models
ImmunoCellular Therapeutics' time-series forecasting models is one of many ImmunoCellular Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary ImmunoCellular Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about ImmunoCellular Therapeutics
Checking the ongoing alerts about ImmunoCellular Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for ImmunoCellular Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| ImmunoCellular Therapeutics is not yet fully synchronised with the market data | |
| ImmunoCellular Therapeutics has some characteristics of a very speculative penny stock | |
| ImmunoCellular Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.15 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ImmunoCellular Therapeutics currently holds about 933.15 K in cash with (2.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 95.0% of the company shares are held by company insiders |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |